Attovia Therapeutics Appoints Tao Fu as Chief Executive Officer

Alamar Biosciences and Frazier Life Sciences announced the launch of Attovia Therapeutics, with a leadership team consisting of Tao Fu as CEO, Petter Veiby as Chief Scientific Officer, Hangjun Zhan as Chief Technology Officer, and Zaneta Odrowaz as Chief Business Officer.

Tao Fu brings over 25 years of executive experience in the pharmaceutical and biotech industries to his role as CEO of Attovia Therapeutics. Previously, he held leadership positions at Zai Lab, Portola Pharmaceuticals, Bristol-Myers Squibb, and Johnson & Johnson.

Petter Veiby, Prior to joining Attovia, held scientific leadership roles at prominent biotech companies and contributed to the advancement of innovative therapeutic approaches.

Hangjun Zhan brings valuable expertise in technology development and implementation.

Zaneta Odrowaz brings her strategic insights and business acumen to foster growth and partnerships for the company.

Attovia Therapeutics is a newly formed company that aims to develop a pipeline of biotherapeutics targeting immune-mediated diseases and cancer.